Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies

Launched by SINGAPORE GENERAL HOSPITAL · Apr 13, 2007

Keywords

ClinConnect Summary

1. Patient inclusion criteria This trial includes only patients who have relapsed after an allogeneic transplant, who have either 1.1 No response to conventional DLI given for at least one dose, or 1.2 No possibility of access to large number of donor lymphocyte for repeated doses of DLI, This applies to cases of unrelated transplant or cord blood transplant

1,3 Patients who developed significant GVHD to conventional DLI, but had no other therapeutic option. In such cases the rationale is based on mice studies of mismatched CIK producing much less GVHD than mismatched unmanipulated sple...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• This trial includes only patients who have relapsed after an allogeneic transplant, who have either:
• • 1. No response to conventional DLI given for at least one dose, or
• • 2. No possibility of access to large number of donor lymphocyte for repeated doses of DLI, This applies to cases of unrelated transplant or cord blood transplant
• • 3. Patients who developed significant GVHD to conventional DLI, but had no other therapeutic option. In such cases the rationale is based on mice studies of mismatched CIK producing much less GVHD than mismatched unmanipulated splenocytes.
• • In view of the period taken to culture the cell to maturity, patient must have a life expectancy of more than one month. Interim measures eg chemotherapy or conventional DLI will be given during the interval so that ongoing treatment will not be compromised in any way.
• Exclusion Criteria:
• • 1. Uncontrolled infection or significant bleeding
• • 2. Unstable vital signs
• • 3. Any degree of hypoxia requiring oxygen therapy.